Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure.

[1]  M. Vaduganathan,et al.  Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial , 2016, European journal of heart failure.

[2]  S. Solomon,et al.  Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. , 2013, JAMA.

[3]  C. Yancy,et al.  Association of Arginine Vasopressin Levels With Outcomes and the Effect of V2 Blockade in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Insights From the EVEREST Trial , 2013, Circulation: Heart Failure.

[4]  G. Filippatos,et al.  A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial , 2012, Heart Failure Reviews.

[5]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[6]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[7]  K. Swedberg,et al.  Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure , 2007 .

[8]  D. DeMets,et al.  Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). , 2005, Journal of cardiac failure.

[9]  R. Purssell,et al.  Derivation and validation of a formula to calculate the contribution of ethanol to the osmolal gap. , 2001, Annals of emergency medicine.

[10]  S. Yusuf,et al.  Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. , 1994, Journal of the American College of Cardiology.

[11]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.